{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T10:52:15Z","timestamp":1774263135025,"version":"3.50.1"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T00:00:00Z","timestamp":1534550400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s11892-018-1065-6","type":"journal-article","created":{"date-parts":[[2018,8,18]],"date-time":"2018-08-18T04:19:02Z","timestamp":1534565942000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology"],"prefix":"10.1007","volume":"18","author":[{"given":"Paola","family":"Lucidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Porcellati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geremia B.","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine G.","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,18]]},"reference":[{"key":"1065_CR1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.2337\/diacare.28.5.1245","volume":"28","author":"Workgroup on Hypoglycemia, American Diabetes Association","year":"2005","unstructured":"Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245\u20139.","journal-title":"Diabetes Care"},{"key":"1065_CR2","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384\u201395.","journal-title":"Diabetes Care"},{"key":"1065_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2337\/dc16-2215","volume":"40","author":"International Hypoglycemia Study Group","year":"2017","unstructured":"International Hypoglycemia Study Group. Glucose concentrations of less than 3.0 mmol\/L [54 mg\/dL] should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40:155\u20137.","journal-title":"Diabetes Care"},{"key":"1065_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.2337\/dc10-1915","volume":"34","author":"SS Johnston","year":"2011","unstructured":"Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34:1164\u201370.","journal-title":"Diabetes Care"},{"key":"1065_CR5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2337\/dc09-2082","volume":"33","author":"CV Desouza","year":"2010","unstructured":"Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33:1389\u201394.","journal-title":"Diabetes Care"},{"key":"1065_CR6","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jama.2009.460","volume":"301","author":"RA Whitmer","year":"2009","unstructured":"Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565\u201372.","journal-title":"JAMA"},{"key":"1065_CR7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/j.1463-1326.2012.01583.x","volume":"14","author":"SS Johnston","year":"2012","unstructured":"Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycemic events and fall-related fractures in medicare-covered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:634\u201343.","journal-title":"Diabetes Obes Metab"},{"key":"1065_CR8","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2337\/dc11-2054","volume":"35","author":"RG McCoy","year":"2012","unstructured":"McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35:1897\u2013901.","journal-title":"Diabetes Care"},{"key":"1065_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.diabres.2012.01.002","volume":"96","author":"AJ Green","year":"2012","unstructured":"Green AJ, Fox KM, Grandy S, SHIELD Study Group. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;96:313\u20138.","journal-title":"Diabetes Res Clin Pract"},{"key":"1065_CR10","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.2337\/dc10-2424","volume":"34","author":"N Laiteerapong","year":"2011","unstructured":"Laiteerapong N, Karter AJ, Liu JY, Moffet HH, Sudore R, Schillinger D, et al. Correlates of quality of life in older adults with diabetes: the diabetes & aging study. Diabetes Care. 2011;34:1749\u201353.","journal-title":"Diabetes Care"},{"key":"1065_CR11","first-page":"186","volume":"29","author":"LA Leiter","year":"2005","unstructured":"Leiter LA, Yale J-F, Chiasson JL, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29:186\u201392.","journal-title":"Can J Diabetes"},{"key":"1065_CR12","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s00125-007-0820-z","volume":"50","author":"ES Kilpatrick","year":"2007","unstructured":"Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50:2553\u201361.","journal-title":"Diabetologia"},{"key":"1065_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1089\/dia.2017.0388","volume":"20","author":"S Rama Chandran","year":"2018","unstructured":"Rama Chandran S, Tay WL, Lye WK, Lim LL, Ratnasingam J, Tan ATB, et al. Beyond HbA1c: comparing glycemic variability and glycemic indices in predicting hypoglycemia in type 1 and type 2 diabetes. Diabetes Technol Ther. 2018;20:353\u201362.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR14","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1056\/NEJM198406283102605","volume":"310","author":"GB Bolli","year":"1984","unstructured":"Bolli GB, Dimitriadis GD, Pehling GB, Baker BA, Haymond MW, Cryer PE, et al. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N Engl J Med. 1984;310:1706\u201311.","journal-title":"N Engl J Med"},{"key":"1065_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/pedi.12070","volume":"15","author":"AM Arbelaez","year":"2014","unstructured":"Arbelaez AM, Xing D, Cryer PE, Kollman C, Beck RW, Sherr J, et al. Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatr Diabetes. 2014;15:127\u201334.","journal-title":"Pediatr Diabetes"},{"key":"1065_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1056\/NEJMra1215228","volume":"369","author":"PE Cryer","year":"2013","unstructured":"Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362\u201372.","journal-title":"N Engl J Med"},{"key":"1065_CR17","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.2337\/diab.42.11.1683","volume":"42","author":"C Fanelli","year":"1993","unstructured":"Fanelli C, Epifano L, Rambotti A, Pampanelli S, Di Vincenzo A, Modarelli F, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42:1683\u20139.","journal-title":"Diabetes"},{"key":"1065_CR18","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2337\/diab.46.7.1172","volume":"46","author":"C Fanelli","year":"1997","unstructured":"Fanelli C, Pampanelli S, Lalli C, Del Sindaco P, Ciofetta M, Lepore M, et al. Long-term intensive therapy of IDDM diabetic patients with clinically overt autonomic neuropathy: effects on awareness of, and counterregulation to hypoglycemia. Diabetes. 1997;46:1172\u201381.","journal-title":"Diabetes"},{"key":"1065_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1056\/NEJM198303033080903","volume":"308","author":"NH White","year":"1983","unstructured":"White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med. 1983;308:485\u201391.","journal-title":"N Engl J Med"},{"key":"1065_CR20","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2337\/diabetes.51.3.724","volume":"51","author":"SA Segel","year":"2002","unstructured":"Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724\u201333.","journal-title":"Diabetes"},{"key":"1065_CR21","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1007\/s00125-007-0599-y","volume":"50","author":"UK Hypoglycemia Study Group","year":"2007","unstructured":"UK Hypoglycemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140\u20137.","journal-title":"Diabetologia"},{"key":"1065_CR22","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/dmrr.482","volume":"20","author":"U Pedersen-Bjergaard","year":"2004","unstructured":"Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, J\u00f8rgensen HV, et al. Severe hypoglycemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479\u201386.","journal-title":"Diabetes Metab Res Rev"},{"key":"1065_CR23","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/0002-9343(91)80085-Z","volume":"90","author":"DCCT research group","year":"1991","unstructured":"DCCT research group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med. 1991;90:450\u20139.","journal-title":"Am J Med"},{"key":"1065_CR24","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00592-015-0713-4","volume":"52","author":"CB Giorda","year":"2015","unstructured":"Giorda CB, Ozzello A, Gentile S, Aglialoro A, Chiambretti A, Baccetti F, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol. 2015;52:845\u201353.","journal-title":"Acta Diabetol"},{"key":"1065_CR25","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2337\/9781580406499","volume-title":"Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention","author":"PE Cryer","year":"2016","unstructured":"Cryer PE. Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. 3rd ed. Alexandria: American Diabetes Association; 2016. p. 3\u20138.","edition":"3"},{"key":"1065_CR26","first-page":"B21","volume":"23","author":"M Shichiri","year":"2000","unstructured":"Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23:B21\u20139.","journal-title":"Diabetes Care"},{"key":"1065_CR27","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2337\/diacare.21.4.574","volume":"21","author":"C Abraira","year":"1998","unstructured":"Abraira C, Henderson W, Colwell J, et al. VA CSDM group. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes [VA feasibility study]. Diabetes Care. 1998;21:574\u20139.","journal-title":"Diabetes Care"},{"key":"1065_CR28","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","volume":"44","author":"The UKPDS Research Group","year":"1995","unstructured":"The UKPDS Research Group. Overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249\u201358.","journal-title":"Diabetes"},{"key":"1065_CR29","first-page":"2","volume":"3","author":"CB Giorda","year":"2014","unstructured":"Giorda CB, Ozzello A, Gentile S, Corsi A, Iannarelli R, Baccetti F, et al. Incidence and correlates of hypoglycemia in type 2 diabetes. The Hypos-1 study. J Diabetes Metab. 2014;3:2.","journal-title":"J Diabetes Metab"},{"key":"1065_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1210\/edrv-12-4-356","volume":"12","author":"JE Gerich","year":"1991","unstructured":"Gerich JE, Mokan M, Veneman T, Korytkowski M, Mitrakou A. Hypoglycemia unawareness. Endocr Rev. 1991;12:356\u201371.","journal-title":"Endocr Rev"},{"key":"1065_CR31","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1464-5491.2008.02413.x","volume":"25","author":"J Geddes","year":"2008","unstructured":"Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycemia in adults with type 1 diabetes. Diabet Med. 2008;25:501\u20134.","journal-title":"Diabet Med"},{"key":"1065_CR32","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/dme.12496","volume":"31","author":"SE Olsen","year":"2014","unstructured":"Olsen SE, Asvold BO, Frier BM, Aune SE, Hansen LI, Bj\u00f8rgaas MR. Hypoglycemia symptoms and impaired awareness of hypoglycemia in adults with type 1 diabetes: the association with diabetes duration. Diabet Med. 2014;31:1210\u20137.","journal-title":"Diabet Med"},{"key":"1065_CR33","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1046\/j.1464-5491.2003.01072.x","volume":"20","author":"JN Henderson","year":"2003","unstructured":"Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016\u201321.","journal-title":"Diabet Med"},{"key":"1065_CR34","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2337\/dc11-0996","volume":"35","author":"ER Seaquist","year":"2012","unstructured":"Seaquist ER, Miller ME, Bonds DE, Feinglos M, Goff DC Jr, Peterson K, et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care. 2012;35:409\u201314.","journal-title":"Diabetes Care"},{"issue":"6168","key":"1065_CR35","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S0140-6736(00)76968-6","volume":"238","author":"RD Lawrence","year":"1941","unstructured":"Lawrence RD. Insulin hypoglycaemia: changes in nervous manifestations. Lancet. 1941;238(6168):602.","journal-title":"Lancet"},{"key":"1065_CR36","doi-asserted-by":"crossref","first-page":"76","DOI":"10.2337\/9781580406499","volume-title":"Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention","author":"PE Cryer","year":"2016","unstructured":"Cryer PE. Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. 3rd ed. Alexandria: American Diabetes Association; 2016. p. 76\u2013109.","edition":"3"},{"key":"1065_CR37","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.2337\/dc15-0533","volume":"38","author":"S Dagogo-Jack","year":"2015","unstructured":"\u2022 Dagogo-Jack S. Philip E. Cryer, MD: seminal contributions to the understanding of hypoglycemia and glucose counterregulation and the discovery of HAAF (Cryer syndrome). Diabetes Care. 2015;38:2193\u20139. A good review of HAAF and its role in the development of severe hypoglycemia.","journal-title":"Diabetes Care"},{"key":"1065_CR38","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1172\/JCI116302","volume":"91","author":"SE Dagogo-Jack","year":"1993","unstructured":"Dagogo-Jack SE, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 1993;91:819\u20138.","journal-title":"J Clin Invest"},{"key":"1065_CR39","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2337\/diacare.18.4.523","volume":"18","author":"D Cox","year":"1995","unstructured":"Cox D, Gonder-Frederick L, Polonsky W, Schlundt D, Julian D, Clarke W. A multicenter evaluation of blood glucose awareness training-II. Diabetes Care. 1995;18:523\u20138.","journal-title":"Diabetes Care"},{"key":"1065_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/diacare.17.1.1","volume":"17","author":"DJ Cox","year":"1994","unstructured":"Cox DJ, Gonder-Frederick L, Julian DM, Clarke W. Long-term follow-up evaluation of blood glucose awareness training. Diabetes Care. 1994;17:1\u20135.","journal-title":"Diabetes Care"},{"key":"1065_CR41","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.2337\/dc11-1579","volume":"35","author":"D Hopkins","year":"2012","unstructured":"Hopkins D, Lawrence I, Mansell P, Thompson G, Amiel S, Campbell M, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care. 2012;35:1638\u201342.","journal-title":"Diabetes Care"},{"key":"1065_CR42","doi-asserted-by":"publisher","first-page":"863","DOI":"10.2337\/dc13-1245","volume":"37","author":"N Zoysa de","year":"2014","unstructured":"de Zoysa N, Rogers H, Stadler M, Gianfrancesco C, Beveridge S, Britneff E, et al. A psychoeducational program to restore hypoglycemia awareness: the DAFNE-HART pilot study. Diabetes Care. 2014;37:863\u20136.","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"1065_CR43","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.2337\/dc08-s227","volume":"31","author":"P Rossetti","year":"2008","unstructured":"Rossetti P, Porcellati F, Bolli GB, Fanelli CG. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes. Diabetes Care. 2008;31(Suppl 2):S113\u201320.","journal-title":"Diabetes Care"},{"key":"1065_CR44","series-title":"Frontiers in diabetes","first-page":"1","volume-title":"Technological Advances in the Treatment of Type 1 Diabetes","author":"GB Bolli","year":"2015","unstructured":"Bolli GB, Porcellati F, Lucidi P, Fanelli CG. Glucose control in diabetes: targets and therapy. In: Bruttomesso D, Grassi G, editors. Technological Advances in the Treatment of Type 1 Diabetes, Frontiers in diabetes, vol. 24; 2015. p. 1\u201310."},{"key":"1065_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","volume":"318","author":"W Lane","year":"2017","unstructured":"\u2022 Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318:33\u201344. A trial examining the risk of hypoglycemia with insulin degludec vs glargine U100 in T1DM subjects at high risk for severe hypoglycemia.","journal-title":"JAMA"},{"key":"1065_CR46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2017.7117","volume":"318","author":"C Wysham","year":"2017","unstructured":"Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318:45\u201356.","journal-title":"JAMA"},{"key":"1065_CR47","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2337\/dc15-0249","volume":"38","author":"PD Home","year":"2015","unstructured":"Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with yype 1 diabetes: a randomized, phase 3a, open-label clinical trial [EDITION 4]. Diabetes Care. 2015;38:2217\u201325.","journal-title":"Diabetes Care"},{"key":"1065_CR48","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dom.13048","volume":"20","author":"PD Home","year":"2018","unstructured":"Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U\/mL versus glargine 100 U\/mL in people with type 1 diabetes [EDITION 4]. Diabetes Obes Metab. 2018;20:121\u20138.","journal-title":"Diabetes Obes Metab"},{"key":"1065_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/dom.12485","volume":"17","author":"R Ritzel","year":"2015","unstructured":"Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U\/ml versus glargine 100 U\/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859\u201367.","journal-title":"Diabetes Obes Metab"},{"issue":"suppl. 1","key":"1065_CR50","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.2337\/dc18-S006","volume":"41","author":"The American Diabetes Association","year":"2018","unstructured":"The American Diabetes Association. Glycemic targets: Standards of medical care in diabetes. Diabetes Care. 2018;41(suppl. 1):S55\u201364.","journal-title":"Diabetes Care"},{"key":"1065_CR51","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2337\/dc16-2201","volume":"40","author":"JC Pickup","year":"2017","unstructured":"Pickup JC, Reznik Y, Sutton AJ. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data meta-analysis and meta-regression of randomized controlled trials. Diabetes Care. 2017;40:715\u201322.","journal-title":"Diabetes Care"},{"key":"1065_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12020-016-1039-x","volume":"55","author":"K Benkhadra","year":"2017","unstructured":"Benkhadra K, Alahdab F, Tamhane SU, McCoy RG, Prokop LJ, Murad MH. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2017;55:77\u201384.","journal-title":"Endocrine"},{"key":"1065_CR53","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/dom.12287","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:833\u201340.","journal-title":"Diabetes Obes Metab"},{"key":"1065_CR54","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","unstructured":"The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977\u201386.","journal-title":"N Engl J Med"},{"key":"1065_CR55","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.2337\/dc12-1770","volume":"36","author":"KM Miller","year":"2013","unstructured":"Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013;36:2009\u201314.","journal-title":"Diabetes Care"},{"issue":"3","key":"1065_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3390\/electronics6030065","volume":"6","author":"G Cappon","year":"2017","unstructured":"\u2022 Cappon G, Acciaroli G, Vettoretti M, Facchinetti A, Sparacino G. Wearable continuous glucose monitoring sensors: a revolution in diabetes treatment. Electronics. 2017;6(3):65. This article presents a thorough overview of CGM sensor technologies.","journal-title":"Electronics"},{"key":"1065_CR57","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.2337\/dci17-0043","volume":"40","author":"JR Petrie","year":"2017","unstructured":"Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L. Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2017;40:1614\u201321.","journal-title":"Diabetes Care"},{"key":"1065_CR58","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.2337\/dc10-2411","volume":"34","author":"P Choudhary","year":"2011","unstructured":"Choudhary P, Shin J, Wang Y, Evans ML, Hammond PJ, Kerr D, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care. 2011;34:2023\u20135.","journal-title":"Diabetes Care"},{"key":"1065_CR59","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1056\/NEJMoa1303576","volume":"369","author":"RM Bergenstal","year":"2013","unstructured":"Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al. ASPIRE in-home study group threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224\u201332.","journal-title":"N Engl J Med"},{"key":"1065_CR60","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.2337\/dc09-2303","volume":"33","author":"B Buckingham","year":"2010","unstructured":"Buckingham B, Chase HP, Dassau E, Cobry E, Clinton P, Gage V, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care. 2010;33:1013\u20137.","journal-title":"Diabetes Care"},{"key":"1065_CR61","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1089\/dia.2016.0216","volume":"18","author":"A Zhong","year":"2016","unstructured":"\u2022 Zhong A, Choudhary P, McMahon C, Agrawal P, Welsh JB, Cordero TL, et al. Effectiveness of automated insulin management features of the MiniMed\u00ae 640G sensor-augmented insulin pump. Diabetes Technol Ther. 2016;18:657\u201363. This article reports an analysis of real-world usage patterns of MiniMed 640G use and predictive pump suspension.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR62","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1089\/dia.2015.0364","volume":"18","author":"MB Abraham","year":"2016","unstructured":"\u2022 Abraham MB, de Bock M, Paramalingam N, O'Grady MJ, Ly TT, George C, et al. Prevention of insulin-induced hypoglycemia in type 1 diabetes with predictive low glucose management system. Diabetes Technol Ther. 2016;18:436\u201343. This study examines the effectiveness of predictive low glucose management (PLGM) system in preventing insulin-induced hypoglycemia.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR63","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1089\/dia.2016.0141","volume":"18","author":"MB Abraham","year":"2016","unstructured":"Abraham MB, Davey R, O'Grady MJ, Ly TT, Paramalingam N, Fournier PA, et al. Effectiveness of a predictive algorithm in the prevention of exercise-induced hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2016;18:543\u201350.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR64","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1089\/dia.2013.0327","volume":"16","author":"T Danne","year":"2014","unstructured":"Danne T, Tsioli C, Kordonouri O, Blaesig S, Remus K, Roy A, et al. The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise. Diabetes Technol Ther. 2014;16:338\u201347.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR65","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1089\/dia.2016.0349","volume":"19","author":"T Biester","year":"2017","unstructured":"\u2022 Biester T, Kordonouri O, Holder M, Remus K, Kieninger-Baum D, Wadien T, et al. \u201cLet the algorithm do the work\u201d: reduction of hypoglycemia using sensor-augmented pump therapy with predictive insulin suspension [SmartGuard] in pediatric type 1 diabetes patients. Diabetes Technol Ther. 2017;19:173\u201382. This study examines the effectiveness of predictive low glucose suspend in preventing hypoglycemia in a pediatric population.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR66","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00592-016-0927-0","volume":"54","author":"AE Scaramuzza","year":"2017","unstructured":"Scaramuzza AE, Arnaldi C, Cherubini V, Piccinno E, Rabbone I, Toni S, et al. Use of the predictive low glucose management (PLGM) algorithm in Italian adolescents with type 1 diabetes: CareLink data download in a real-world setting. Acta Diabetol. 2017;54:317\u20139.","journal-title":"Acta Diabetol"},{"key":"1065_CR67","series-title":"Endocrinology","first-page":"1","volume-title":"Diabetes complications, comorbidities and related disorders","author":"CG Fanelli","year":"2018","unstructured":"Fanelli CG, Lucidi P, Bolli GB, Porcellati F. Hypoglycemia. In: Bonora E, DeFronzo R, editors. Diabetes complications, comorbidities and related disorders, Endocrinology. Cham: Springer; 2018. p. 1\u201338."},{"key":"1065_CR68","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1089\/dia.2010.0028","volume":"12","author":"M Gim\u00e9nez","year":"2010","unstructured":"Gim\u00e9nez M, Lara M, Conget I. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study. Diabetes Technol Ther. 2010;12:517\u201321.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR69","doi-asserted-by":"publisher","first-page":"336","DOI":"10.7326\/0003-4819-157-5-201209040-00508","volume":"157","author":"HC Yeh","year":"2012","unstructured":"Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157:336\u201347.","journal-title":"Ann Intern Med"},{"key":"1065_CR70","doi-asserted-by":"publisher","first-page":"d3805","DOI":"10.1136\/bmj.d3805","volume":"343","author":"JC Pickup","year":"2011","unstructured":"Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805.","journal-title":"BMJ"},{"key":"1065_CR71","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.2337\/dc14-0030","volume":"37","author":"SA Little","year":"2014","unstructured":"Little SA, Leelarathna L, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 \u00d7 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring [HypoCOMPaSS]. Diabetes Care. 2014;37:2114\u201322.","journal-title":"Diabetes Care"},{"key":"1065_CR72","doi-asserted-by":"publisher","unstructured":"\u2022 Little SA, Speight J, Leelarathna L, Walkinshaw E, Tan HK, Bowes A, et al. Sustained reduction in severe hypoglycemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: 2-year follow-up in the HypoCOMPaSS randomized clinical trial. Diabetes Care. 2018; https:\/\/doi.org\/10.2337\/dc17-2682 . The study highlights the importance of the structured approach, patient education, and follow-up in specialized centers as the determining factor in reducing hypoglycemia and improving the awareness of hypoglycemia, even independent of technology.","DOI":"10.2337\/dc17-2682"},{"key":"1065_CR73","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jama.2013.277818","volume":"310","author":"TT Ly","year":"2013","unstructured":"Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310:1240\u20137.","journal-title":"JAMA"},{"key":"1065_CR74","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/1932296815597918","volume":"10","author":"L Heinemann","year":"2015","unstructured":"Heinemann L, Hermanns N. IQWiG reanalyzes and raises questions about an article by Ly et al which concluded low glucose suspend is very beneficial. J Diabetes Sci Technol. 2015;10:185\u201390.","journal-title":"J Diabetes Sci Technol"},{"key":"1065_CR75","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/S2213-8587(16)30193-0","volume":"4","author":"CA Beers van","year":"2016","unstructured":"\u2022 van Beers CA, DeVries JH, Kleijer SJ, Smits MM, Geelhoed-Duijvestijn PH, Kramer MH, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia [IN CONTROL]: a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4:893\u2013902. This trial investigated the use of continuous glucose monitoring (CGM) in patients with type 1 diabetes and impaired awareness of hypoglycaemia.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1065_CR76","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/jc.2017-01516","volume":"103","author":"MR Rickels","year":"2018","unstructured":"\u2022 Rickels MR, Peleckis AJ, Dalton-Bakes C, Naji JR, Ran NA, Nguyen HL, et al. Continuous glucose Mmonitoring for hypoglycemia avoidance and glucose counterregulation in long-Sstanding type 1 diabetes. J Clin Endocrinol Metab. 2018;103:105\u201314. This study used real-time CGM as a strategy for prevention of hypoglycemia to assess whether such prevention could improve glucose counterregulation measured by the EGP response to insulin-induced hypoglycemia in patients with long-standing T1D complicated by hypoglycemia unawareness.","journal-title":"J Clin Endocrinol Metab"},{"key":"1065_CR77","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/dia.2016.0332","volume":"19","author":"AM G\u00f3mez","year":"2017","unstructured":"\u2022 G\u00f3mez AM, Mar\u00edn Carrillo LF, Mu\u00f1oz Velandia OM, Rond\u00f3n Sep\u00falveda MA, Ar\u00e9valo Correa CM, Mora Garz\u00f3n E, et al. Long-term efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetes. Diabetes Technol Ther. 2017;19:109\u201314. A study describing the long-term outcomes of SAP therapy with low-glucose suspend feature (SAP+LGS) in hypoglycemia in a Colombian population with T1D and hypoglycemia unawareness.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR78","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(18)30297-6","volume":"391","author":"L Heinemann","year":"2018","unstructured":"\u2022\u2022 Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections [HypoDE]: a multicentre, randomised controlled trial. Lancet. 2018;391:1367\u201377. A trial with potential broad application that has evaluated the effectiveness of RT-CGM in avoidance of hypoglycemia among high-risk individuals with type 1 diabetes in SMBG and treated with MDI.","journal-title":"Lancet"},{"key":"1065_CR79","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/S0140-6736(16)31535-5","volume":"388","author":"J Bolinder","year":"2016","unstructured":"\u2022 Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kr\u00f6ger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254\u201363. A trial showing a reduction in the mean time spent in hypoglycemia by using a factory-calibrated, sensor-based, flash glucose-monitoring system compared with self-monitored glucose testing in patients with type 1 diabetes.","journal-title":"Lancet"},{"key":"1065_CR80","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s13300-016-0223-6","volume":"8","author":"T Haak","year":"2017","unstructured":"Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55\u201373.","journal-title":"Diabetes Ther"},{"key":"1065_CR81","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/M16-2855","volume":"167","author":"RW Beck","year":"2017","unstructured":"\u2022 Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365\u201374. A 24-week randomized trial comparing the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin.","journal-title":"Ann Intern Med"},{"key":"1065_CR82","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1177\/1932296815581052","volume":"9","author":"RR Gehlaut","year":"2015","unstructured":"Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes--more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol. 2015;9:999\u20131005.","journal-title":"J Diabetes Sci Technol"},{"key":"1065_CR83","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.jcjd.2015.05.007","volume":"39","author":"M Pazos-Couselo","year":"2015","unstructured":"Pazos-Couselo M, Garc\u00eda-L\u00f3pez JM, Gonz\u00e1lez-Rodr\u00edguez M, Gude F, May\u00e1n-Santos JM, Rodr\u00edguez-Segade S, et al. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study. Can J Diabetes. 2015;39:428\u201333.","journal-title":"Can J Diabetes"},{"key":"1065_CR84","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1056\/NEJMoa1314474","volume":"371","author":"SJ Russell","year":"2014","unstructured":"Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313\u201325.","journal-title":"N Engl J Med"},{"key":"1065_CR85","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S2213-8587(17)30167-5","volume":"5","author":"A Weisman","year":"2017","unstructured":"Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:501\u201312.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1065_CR86","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S2213-8587(15)00489-1","volume":"4","author":"SJ Russell","year":"2016","unstructured":"Russell SJ, Hillard MA, Balliro C, Magyar KL, Selagamsetty R, Sinha M, et al. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016;4:233\u201343.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1065_CR87","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1089\/dia.2016.0421","volume":"19","author":"SK Garg","year":"2017","unstructured":"\u2022 Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19:155\u201363. A trial evaluating in-home use of the Medtronic MiniMed\u00ae 670G hybrid closed-loop insulin delivery system over 3\u00a0months in both adolescents and adults with type 1 diabetes. None of the participants experienced a severe hypoglycemic or diabetic ketoacidosis, demonstrating the safety of the system.","journal-title":"Diabetes Technol Ther"},{"key":"1065_CR88","doi-asserted-by":"crossref","first-page":"e020274","DOI":"10.1136\/bmjopen-2017-020274","volume":"8","author":"SA McAuley","year":"2018","unstructured":"McAuley SA, de Bock MI, Sundararajan V, Lee MH, Paldus B, Ambler GR, et al. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open. 2018;8:e020274.","journal-title":"BMJ Open"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-018-1065-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-018-1065-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-018-1065-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T12:17:24Z","timestamp":1693829844000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-018-1065-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,18]]},"references-count":88,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s11892-018-1065-6","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,18]]},"assertion":[{"value":"18 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Paola Lucidi has received travel grants to attend international conferences from Sanofi and Menarini.Francesca Porcellati has received honoraria for lectures and consulting from Sanofi, Eli Lilly, Menarini, and Medtronic.Geremia B. Bolli has received honoraria for lectures and consultations from Sanofi, Novartis, and Lilly.Carmine G. Fanelli has received honoraria for consulting from Sanofi, and travel grants to attend international conferences from Menarini.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"83"}}